Sedana Medical

According to the financial calendar, Sedana Medical plans to publish the interim report for the third quarter of 2026 on Thursday, October 22, at approximately 07:00 CET. Sedana Medical hereby invites you to a presentation of the report on the same day, at which CEO Johannes Doll, together with Mikael Haag, CFO, and Peter Sackey, CMO, will present the report in English and answer questions.

Date: Thursday, October 22, 2026
Time (CET): 13:30

More information and a link to the audiocast:  https://www.finwire.tv/webcast/sedana-medical/q3-2026/

To participate via teleconference, call +46 8 446 824 88. Enter meeting ID 883 3639 6866, followed by #.

Welcome!

For additional information, please contact:
Johannes Doll, CEO, +46 (0)76 303 66 66
Mikael Haag, CFO, +46 (0)79 583 42 59
ir@sedanamedical.com

About Sedana Medical
Sedana Medical AB (publ) is a pioneering medical technology and pharmaceutical company focused on inhaled sedation to improve patients’ lives during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe, as well as in Asia, Australia, Canada, and South and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA), and is headquartered in Stockholm, Sweden.